{"id":"https://openalex.org/W1983259667","doi":"https://doi.org/10.1038/clpt.2011.220","title":"The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects","display_name":"The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects","publication_year":2011,"publication_date":"2011-12-28","ids":{"openalex":"https://openalex.org/W1983259667","doi":"https://doi.org/10.1038/clpt.2011.220","mag":"1983259667","pmid":"https://pubmed.ncbi.nlm.nih.gov/22205195"},"language":"en","primary_location":{"id":"doi:10.1038/clpt.2011.220","doi":"https://doi.org/10.1038/clpt.2011.220","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2011.220","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071455700","display_name":"Daniel E. Salazar","orcid":"https://orcid.org/0000-0002-8081-9280","observed_orcids":["https://orcid.org/0000-0002-8081-9280"]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"D E Salazar","raw_affiliation_strings":["Daiichi Sankyo Pharma Development, Edison, New Jersey, USA. dsalazar@dsi.com","Daiichi Sankyo Pharma Development, Edison, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, Edison, New Jersey, USA. dsalazar@dsi.com","institution_ids":["https://openalex.org/I4210162815"]},{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, Edison, New Jersey, USA","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105836356","display_name":"Shuxian Song","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S H Song","raw_affiliation_strings":["Daiichi Sankyo Pharma Development, Edison, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, Edison, New Jersey, USA","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014517230","display_name":"Jingpu Shi","orcid":"https://orcid.org/0000-0002-7893-8707","observed_orcids":["https://orcid.org/0000-0002-7893-8707"]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]},{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Shi","raw_affiliation_strings":["Allergan, Inc., Irvine, California, USA","Daiichi Sankyo Pharma Development, Edison, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allergan, Inc., Irvine, California, USA","institution_ids":["https://openalex.org/I4210139498"]},{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, Edison, New Jersey, USA","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035083183","display_name":"Shashank Rohatagi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]},{"id":"https://openalex.org/I899992584","display_name":"Piramal (India)","ror":"https://ror.org/00vj60w13","country_code":"IN","type":"company","lineage":["https://openalex.org/I899992584"]}],"countries":["IN","US"],"is_corresponding":false,"raw_author_name":"S Rohatagi","raw_affiliation_strings":["Daiichi Sankyo Pharma Development, Edison, New Jersey, USA","Nicholas Piramal India Limited, Mumbai, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, Edison, New Jersey, USA","institution_ids":["https://openalex.org/I4210162815"]},{"raw_affiliation_string":"Nicholas Piramal India Limited, Mumbai, India","institution_ids":["https://openalex.org/I899992584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014478200","display_name":"Reinilde Heyrman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R Heyrman","raw_affiliation_strings":["Daiichi Sankyo Pharma Development, Edison, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, Edison, New Jersey, USA","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050737404","display_name":"Daisuke Wada","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D R Wada","raw_affiliation_strings":["Pharsight Corporation, Sunnyvale, California, USA","Quantitative Solutions, Menlo Park, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharsight Corporation, Sunnyvale, California, USA","institution_ids":[]},{"raw_affiliation_string":"Quantitative Solutions, Menlo Park, California, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065766712","display_name":"Timothy J. Carrothers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T J Carrothers","raw_affiliation_strings":["Pharsight Corporation, Sunnyvale, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharsight Corporation, Sunnyvale, California, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5071455700"],"corresponding_institution_ids":["https://openalex.org/I4210162815"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":0.9122,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.76541774,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"91","issue":"2","first_page":"250","last_page":"256"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.013899999670684338,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.007600000128149986,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olmesartan-medoxomil","display_name":"olmesartan medoxomil","score":1.0},{"id":"https://openalex.org/keywords/pediatric-hypertension","display_name":"pediatric hypertension","score":0.9909999966621399},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.7480000257492065},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.6470000147819519},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.6600000262260437},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6710000038146973},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.593999981880188},{"id":"https://openalex.org/keywords/model-based-prediction","display_name":"model-based prediction","score":0.39399999380111694},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.7170000076293945}],"concepts":[{"id":"https://openalex.org/C2779766728","wikidata":"https://www.wikidata.org/wiki/Q421156","display_name":"Olmesartan","level":3,"score":0.9371086359024048},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7626461386680603},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7472058534622192},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.7292264699935913},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.6690285205841064},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6256062984466553},{"id":"https://openalex.org/C147583825","wikidata":"https://www.wikidata.org/wiki/Q620876","display_name":"Body weight","level":2,"score":0.441596120595932},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.415942907333374},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41011014580726624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3260813355445862},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068557","descriptor_name":"Olmesartan Medoxomil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003198","descriptor_name":"Computer Simulation","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007223","descriptor_name":"Infant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015233","descriptor_name":"Models, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1038/clpt.2011.220","doi":"https://doi.org/10.1038/clpt.2011.220","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2011.220","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:22205195","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22205195","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1497461844","https://openalex.org/W2016487162","https://openalex.org/W2018103624","https://openalex.org/W2032595010","https://openalex.org/W2035446971","https://openalex.org/W2038286610","https://openalex.org/W2039657099","https://openalex.org/W2043640056","https://openalex.org/W2061382407","https://openalex.org/W2066328476","https://openalex.org/W2069332856","https://openalex.org/W2092249899","https://openalex.org/W2156210803","https://openalex.org/W2171673811","https://openalex.org/W2288605373"],"related_works":["https://openalex.org/W2050597223","https://openalex.org/W2196811476","https://openalex.org/W4407698685","https://openalex.org/W1234141168","https://openalex.org/W2572716593","https://openalex.org/W2518445299","https://openalex.org/W2069332856","https://openalex.org/W2884640895","https://openalex.org/W4311022731","https://openalex.org/W3175928417"],"abstract_inverted_index":{"Modeling":[0],"and":[1,85,92,137],"simulation":[2],"were":[3,36,107],"used":[4],"extensively":[5],"in":[6,18,28,95,109,121],"the":[7,13,47,53,66,70,99,110],"development":[8],"of":[9,15,49,69,101,129],"an":[10,117],"indication":[11],"for":[12,52,60,98,132,140],"use":[14],"olmesartan":[16,118],"medoxomil":[17],"pediatric":[19,56,111,122],"patients":[20,30],"with":[21,65,80],"hypertension.":[22],"Simulations":[23],"based":[24],"on":[25,104],"models":[26],"developed":[27],"adult":[29],"indicated":[31],"that":[32],"two":[33],"dose":[34],"groups":[35],"sufficient":[37],"to":[38,82,126],"estimate":[39],"a":[40],"dose-response":[41,78],"relationship,":[42],"thereby":[43],"reducing":[44],"by":[45],"one-third":[46],"number":[48],"subjects":[50,123,133],"required":[51],"phase":[54,72],"III":[55,73],"study.":[57],"Model-based":[58],"predictions":[59],"blood":[61,87],"pressure":[62],"reduction":[63],"agreed":[64],"observed":[67],"results":[68],"subsequent":[71],"study,":[74],"showing":[75],"statistically":[76],"significant":[77],"relationships":[79,94],"respect":[81],"both":[83],"systolic":[84],"diastolic":[86],"pressure.":[88],"Previously":[89],"established":[90],"pharmacokinetic":[91],"exposure-response":[93],"adults,":[96],"adjusted":[97],"influence":[100],"body":[102],"weight":[103],"clearance":[105],"(wt(0.80)),":[106],"confirmed":[108],"population.":[112],"Together,":[113],"these":[114],"findings":[115],"support":[116],"dosing":[119],"recommendation":[120],"aged":[124],"6":[125],"16":[127],"years":[128],"10":[130],"mg":[131,139],"weighing":[134,142],"<35":[135],"kg":[136],"20":[138],"those":[141],"\u226535":[143],"kg.":[144]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}